In a cohort of patients diagnosed with HR+, HER2− advanced breast cancer, characterized by either de novo metastatic disease or late recurrence following neoadjuvant therapy, the frontline combination of ribociclib and letrozole significantly prolonged the OS over letrozole alone. Here, HR is linked to breast carcinoma.